CONVERGE
The facts below are what the maker publishes about CONVERGE, checked and dated. Our editors have not written about it yet.
The facts
Each one read from CONVERGE's own pages, with the date it was checked.
What it does
- Commercial access
- Verge describes engagement models ranging from full target-discovery campaigns to focused human-relevance assessments.checked 14 Nov 2026
- Data collection
- VergeDB is built from brain tissue partnerships and includes transcriptomic, genetic, clinical, and multi-omics data.checked 14 Nov 2026
- Model
- Its model infers an individual patient's brain molecular state from a routine blood draw and predicts drug response.checked 14 Nov 2026
- Product
- CONVERGE is an AI operating system for neuroscience drug development combining foundation models and systems-biology workflows.checked 14 Nov 2026
- Program enablement
- CONVERGE helps teams evaluate target pathways, patient subgroups, preclinical models, and indication opportunities.checked 14 Nov 2026
- Scale
- The company's platform data page reports 12,000 brain transcriptomes, 6,000+ neurological patients and controls, and 15M single-cell profiles.checked 14 Nov 2026
- Security and integrations
- The opened official product pages do not state security certifications or third-party integrations.checked 14 Nov 2026
- Support
- Verge says it aims to reply to platform and partnership inquiries within two business days.checked 14 Nov 2026
- Target discovery
- The platform identifies disease signatures and targets using multimodal patient data and human tissue and genetics.checked 14 Nov 2026
- Training data
- The foundation model is trained on proprietary multimodal CNS patient data and can be tuned with program- and trial-specific data.checked 14 Nov 2026
- Users
- The product is presented for drug developers working on neuroscience and CNS programs.checked 14 Nov 2026
The company
- Company
- Verge Labs says it started as Verge Genomics in 2015 and became Verge Labs in 2026.checked 14 Nov 2026
- Founded
- 2015checked 21 Oct 2026
- Headquarters
- San Francisco, Californiachecked 21 Oct 2026
Money
- Trial optimization
- It stratifies trial populations by molecular endotype and identifies likely-benefit subgroups and pharmacodynamic biomarkers.checked 14 Nov 2026
Alternatives to CONVERGE
- 1
Boltzmann Labs
Free planWebAPI6.7Free plan - 2
Amazon Bio Discovery
Free planWeb6.6From $180 a month - 3
TRION
Free planWebmacOSWindows6.3From $0.01 a month - 46.0Free plan
- 5
StarDrop
WebLinuxmacOSWindows5.7From $10,000 a year - 65.5From $2,500 a month
